CAS 143664-11-3
:Elacridar
- 4-acridinecarboxamide, N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-
- Gf 120918
- Gf 129018
- Gg 918
- Gw 0918
- N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide
- N-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl]phenyl}-5-methoxy-9-oxo-9,10-dihydroacridine-4-carboxamide
- Elacridar
Elacridar
CAS:Formula:C34H33N3O5Purity:>98.0%(HPLC)Color and Shape:White to Yellow to Green powder to crystalMolecular weight:563.65Ref: IN-DA00AOQ8
1g582.00€5gTo inquire1mg49.00€25gTo inquire5mg52.00€10mg64.00€25mg102.00€50mg132.00€100mg156.00€250mg248.00€Elacridar
CAS:Formula:C34H33N3O5Purity:≥ 98.0%Color and Shape:Off-white to yellow powderMolecular weight:563.64Elacridar
CAS:Elacridar (GG918) is a potent inhibitor of P-glycoprotein and BCRP.Cost-effective and quality-assured.Formula:C34H33N3O5Purity:98.12% - >99.99%Color and Shape:SolidMolecular weight:563.64Elacridar
CAS:ElacridarFormula:C34H33N3O5Purity:By hplc: 100% (Typical Value in Batch COA)Color and Shape: solidMolecular weight:563.64g/molElacridar
CAS:Inhibitor of ABC transporters; oral bioenhancer for anti-cancer therapyFormula:C34H33N3O5Purity:Min. 98 Area-%Color and Shape:Yellow PowderMolecular weight:563.64 g/molElacridar - Bio-X ™
CAS:Elacridar is an inhibitor of ATP-dependent transport, which is mediated by P-glycoprotein (P-gp). Functioning as an oral bioenhancer, Elacridar addresses multiple drug resistance in tumors, a common challenge in cancer treatment often linked to changes in the expression of protein inhibitors. Inhibition of P-gp by Elacridar is a key mechanism behind its effectiveness. P-glycoprotein, a well-characterized human ABC transporter of the MDR/TAP subfamily, acts as an ATP-dependent efflux pump with broad substrate specificity. Its increased expression in the intestines can hinder drug absorption, leading to reduced bioavailability and inadequate therapeutic plasma concentrations. Elacridar addresses this challenge by inhibiting P-gp, thereby increasing the bioavailability of coadministered drugs. Overall, Elacridar emerges as a promising option for the treatment of solid tumors, offering a strategic approach to overcoming multidrug resistance in cancer therapy.
Formula:C34H33N3O5Purity:Min. 95%Color and Shape:PowderMolecular weight:563.64 g/molElacridar
CAS:Controlled ProductApplications A prototypical BCRP inhibitor. Inhibits the Bcrp1-mediated transport.
References Neville, K., et al.: Clin. Cancer Res., 10, 2525 (2004), Reardon, D., et al.: J. Clin. Oncol. 23, 9359 (2005), Pan, G., et al.: Drug Metab. Dispos., 35, 1165 (2007),Formula:C34H33N3O5Color and Shape:NeatMolecular weight:563.64







